1. Is the proposal accretive? If so, in which year does it first become accretive, and by what percentage (vs. standalone prior valuation expectation)? Show some sensitivities around this analysis. 2. Show summarized accretion figures for Proposed Transaction, including and excluding synergies. Tips: p1-3 are assumption; p4-5 are Accretion/Diluted Analysis; p6 is Contribution Analysis Transaction Assumptions ($ in millions, except per share data) Summary Financial Data M&A AssumptionsTranche5Tranche6Tranche7Tranche8Tranche9Tranche100.0000.0000.0000.000 0.0000.0000.000.000.000.000.000.000.9490.9490.9490.9490.9490.94948.748.751.3548.748.7 48.748.751.35Total0.00051.3551.3551.3551.350.0000.2510.0000.0000.0000.000 Syneos HealthAccretion / Dilution AnalvsisContribution Analysis ($ in millions, except per share data) R E G C C (1) Excludes acquisition accounting and financing adjustments and synergies. (2) Excludes acquisition accounting and financing adjustments..
1. Is the proposal accretive? If so, in which year does it first become accretive, and by what percentage (vs. standalone prior valuation expectation)? Show some sensitivities around this analysis. 2. Show summarized accretion figures for Proposed Transaction, including and excluding synergies. Tips: p1-3 are assumption; p4-5 are Accretion/Diluted Analysis; p6 is Contribution Analysis Transaction Assumptions ($ in millions, except per share data) Summary Financial Data M&A AssumptionsTranche5Tranche6Tranche7Tranche8Tranche9Tranche100.0000.0000.0000.000 0.0000.0000.000.000.000.000.000.000.9490.9490.9490.9490.9490.94948.748.751.3548.748.7 48.748.751.35Total0.00051.3551.3551.3551.350.0000.2510.0000.0000.0000.000 Syneos HealthAccretion / Dilution AnalvsisContribution Analysis ($ in millions, except per share data) R E G C C (1) Excludes acquisition accounting and financing adjustments and synergies. (2) Excludes acquisition accounting and financing adjustments..